Two 2025 papers are the core of what is known about C15 (pentadecanoic acid) and cancer. A study in BMC Medicine combined human cohort data, cell experiments, a mouse tumour model and gut microbiome analysis in bladder cancer [1]. A screening study in Nutrients tested C15 against 94 human cancer cell lines and found most of its activity in one family of blood cancers [2]. Neither is a trial in people with cancer.
The two papers point in somewhat different directions, which is why we cover them together: the bladder study proposes an effect that runs through the gut, while the screen found no bladder line among its responders. This page walks through both, then the wider evidence on diet and bladder cancer, and what it would take to show that C15 matters for cancer in people.
The Bladder Cancer Study: Four Layers of Evidence
The study stacked four different types of evidence, which is unusual and is the main reason it carries more weight than a typical single-method paper.
Human cohorts. Large-scale cohort analyses found dietary pentadecanoic acid intake negatively associated with both bladder cancer occurrence and invasion. Higher intake, lower observed risk.
Cell lines. In EJ and T24 human bladder cancer cells, C15 suppressed migration, invasion, and proliferation. Those are three distinct behaviours, not one measurement repeated.
A live animal model. This is the part missing from most C15 cancer research. The researchers used BBN-induced bladder cancer in mice, a chemical carcinogen model that produces tumours resembling human bladder cancer. C15 inhibited tumour development in living animals, not just in a dish.
Mechanism. Serum proteomics identified changes in lipid-related proteins including Apoe and Apob. Gut microbiome sequencing showed C15 markedly altered both bacterial populations, notably the genus Alistipes, and fungal populations including Erysiphales, Teberdinia, and Gibberella. Targeted fecal lipidomics found shifts in phosphatidylethanolamines.
The Gut-Bladder Axis Angle
The mechanistic story the authors propose runs through the gut rather than directly through the bladder. The abstract describes C15 as derived from diet by the gut microbiome, and in this study it reshaped the gut microbial community, which in turn shifted lipid metabolism, which correlated with reduced tumour development.
That is a reasonable hypothesis with a real weakness: it is built on correlations between microbiome composition and outcome. The study did not, based on the published abstract, transplant the altered microbiome into another animal to test whether the microbial change is doing the work or is simply happening alongside it. Fecal transplant experiments are the standard way to establish causality in microbiome research, and their absence means the gut-mediated explanation remains the authors’ interpretation rather than a demonstrated pathway.
The inclusion of fungal shifts is unusual and worth noting. Most microbiome work looks only at bacteria, so the fungal data is a genuine addition, though it is also the least characterised and hardest to interpret part of the analysis.
The 94-Cell-Line Screen: Blood Cancers and CCND3
The other significant 2025 C15 cancer paper screened 94 human cancer cell lines at physiologic concentrations and found dose-dependent activity in 13 of them, heavily concentrated in non-Hodgkin B-cell lymphomas with the remainder in liver, breast, and lung lines [2]. No bladder line appeared among the reported responders, and the published abstract does not state whether bladder lines were in the panel at all.
The details are worth having. An independent service ran a commercial assay (the Eurofins OncoPanel) testing C15 at 10 concentrations from 1.5 nanomolar to 50 micromolar. Of the 13 responsive lines (13.8% of 94), 8 were non-Hodgkin B-cell lymphomas, 2 liver, 2 breast and 1 lung. Only four lines responded on all three standard potency measures (EC50, IC50 and GI50), and all four were B-cell lymphomas [2].
The author then compared gene alterations in the 79 lines with data in a public cancer-genetics database. A mutation in CCND3, a gene that helps control cell division and is altered in some lymphomas, was present in 4 of 18 responsive lines (22%) against 1 of 61 non-responsive lines (1.6%), with an odds ratio of 17.1 and a 95% confidence interval of 1.8 to 165 [2].
An interval that wide comes from very small counts, so the true relationship could be modest or large. The paper is a single-author study by a co-founder of the company that commercializes C15, which it discloses, and it was funded by the Office of Naval Research [2].
That is not necessarily a contradiction, and the reason is instructive. The screening study measured whether C15 directly slows cancer cell growth in isolation. The bladder study proposes an effect that runs through the gut microbiome and systemic lipid metabolism, which by definition cannot happen in a cell-culture well with no microbiome and no host. A compound can plausibly show weak direct cytotoxicity while still affecting tumour development in a whole organism through indirect routes.
The bladder study did also find direct effects on EJ and T24 cells, which complicates that clean explanation somewhat. Different cell lines, assays, concentrations, and endpoints can produce different answers, and reconciling them properly would require the two groups to test the same lines under the same conditions.
What This Does Not Establish
The human portion is observational dietary data. Dietary C15 intake tracks dairy consumption, which tracks a whole cluster of dietary and lifestyle patterns, and smoking is by a wide margin the dominant risk factor for bladder cancer. Whether the cohort analyses adjusted adequately for smoking and other confounders cannot be determined from the abstract, and this is the single most important thing to check before treating the human association as meaningful.
There has been no clinical trial. No person with bladder cancer, or at risk of it, has been given C15 and followed for an outcome. The mouse work used a chemically induced model, which is a legitimate tool but is not the same disease as a human bladder tumour arising over decades.
Most directly: nothing here supports taking C15 to prevent or treat cancer, and no supplement should be used in place of, or alongside, cancer treatment without the treating oncologist knowing. Supplements can interact with chemotherapy and immunotherapy in ways that matter.
The Bladder Study in Summary
This is a notably thorough cancer-related C15 study, mainly because it includes a live animal tumour model rather than stopping at cells in a dish, and because it comes from a multi-institution author group that declares no competing interests. The gut-mediated mechanism is plausible but not causally demonstrated, and the human data is observational with substantial confounding potential.
The right way to hold this is as a serious early-stage finding that justifies further research, sitting several steps short of anything that should change what anyone eats or takes.
How Strong Is the Diet and Bladder Cancer Link in General?
Before putting weight on any one dietary association, it helps to see how weak the whole field tends to be. A 2026 systematic review in BJU International (Miyajima et al.) pooled 32 prospective cohort studies covering more than 2.2 million participants and looked at fluid, coffee, milk, tea, alcohol, fruit, vegetables, protein, fiber and cruciferous vegetables. Its conclusion was that the evidence does not support a strong or consistent association between dietary factors and bladder cancer incidence. Most studies were at moderate risk of bias, and residual confounding, particularly by smoking, remained a concern. The reviewers added that dietary changes alone are unlikely to meaningfully alter bladder cancer risk.
Dairy specifically has produced mixed results. A 2020 meta-analysis in Nutrition and Cancer (Wu et al.) pooled 16 studies of milk and 10 of dairy products across about 221,000 people. It reported an inverse association between milk consumption and bladder cancer risk, with the trend more pronounced in case-control studies than in other designs. A 2024 review of risk factors in the International Journal of Environmental Research and Public Health (Alouini), by contrast, lists whole milk among dietary factors linked to bladder cancer development. Those two summaries point in different directions, which is a useful reminder that dairy-derived markers such as C15 can track very different eating patterns in different populations.
Smoking Dwarfs Everything Else
The same 2024 review states that tobacco smoking is the major risk factor for urothelial bladder cancer, because smoke contains aromatic amines and polycyclic aromatic hydrocarbons. It also describes occupational exposure to aromatic amines in dye, paint, petroleum and metal industries as responsible for about 20 percent of cases, and lists air pollution and chlorinated water among other factors. For readers, the lesson is not that diet is irrelevant, but that a modest association between a dietary fatty acid and bladder cancer can be shifted, or erased, by the way smoking, occupation and environment are handled in the statistics. When the abstract of the BMC Medicine paper reports an inverse association, that is exactly where the full paper’s adjustment methods matter most.
Where Gut-Made C15 Fits In
The BMC Medicine abstract describes pentadecanoic acid as an odd-chain fatty acid “derived from diet by the gut microbiome.” That phrasing fits earlier human work. A 2016 review in Advances in Nutrition (Pfeuffer and Jaudszus) notes that odd-chain fatty acids can be synthesized in the body from gut-derived propionic acid. A 2017 randomized crossover study in the American Journal of Clinical Nutrition (Weitkunat et al.) gave 16 healthy adults cellulose, inulin or propionate for 7 days. Inulin and propionate raised pentadecanoic acid in plasma phospholipids by about 17 and 13 percent, while cellulose did not.
My own reasoning from those results, not a claim from any of the papers, is that if fiber intake raises circulating C15 and fiber intake also travels with other healthy habits, then a link between dietary C15 and a cancer outcome could partly reflect overall diet quality rather than the fatty acid itself. Observational data cannot separate the two, which is another reason the live-animal experiment in the bladder paper carries so much of the study’s weight.
Concentrations: A Dish Is Not a Body
Cell studies depend heavily on dose. The 2025 Nutrients paper (Venn-Watson) screened pentadecanoic acid against 94 cancer cell lines at 10 concentrations from 1.5 nanomolar to 50 micromolar and counted a line as responsive when its EC50 was 50 micromolar or lower. That upper limit is easy to misjudge, so here is the conversion. With a molecular weight of about 242, 50 micromolar is roughly 12 micrograms per mL, and 5 micrograms per mL is roughly 20 micromolar. In the 2024 Journal of Nutrition trial (Robinson et al.), half of the people taking 200 mg a day finished above 5 micrograms per mL, while the average gain over placebo was 1.88 micrograms per mL, or roughly 8 micromolar. The abstracts do not say at what concentration each responsive cell line was inhibited, so the closest reading is that some effects may sit within or near the range seen in supplementation and others may require more than people typically reach. The author of that screen is a co-founder of the company that commercializes the ingredient, and the paper discloses this.
A Different Cancer, Same Pattern: Breast Cancer Stem-Like Cells
The bladder paper is not the first cell-level cancer finding. A 2020 study in Nutrients (To et al.) tested pentadecanoic acid in MCF-7/SC human breast cancer stem-like cells. It reported selective cytotoxicity against these cells compared with the parent cell line, reduced stem-like properties and migration, suppression of interleukin-6-induced JAK2/STAT3 signaling, cell cycle arrest and caspase-dependent apoptosis. The authors suggested it could serve as a novel JAK2/STAT3 inhibitor in breast cancer cells. This is a lab result in a single cell line. Taken with the 94-line screen, which found two breast lines among 13 responders, it suggests that responses vary by cell type, so no single cancer type should be assumed to behave like another.
What Convincing Evidence Would Look Like
- Adjusted prospective cohorts that measure blood C15 before diagnosis, report smoking-adjusted results, and separate dairy from fiber effects.
- A causal test of the gut hypothesis, such as transferring the altered microbiome to untreated animals to see whether tumor development changes.
- Head-to-head cell work using the same lines, assays and concentrations across independent laboratories.
- Human trials in carefully chosen populations, with clinical endpoints and oncologist oversight. None of the studies described in this article is a trial in people with cancer.
Until several of those exist, the responsible position is the one the bladder study itself supports: an interesting, plausible, early finding that is not a basis for changing treatment or prevention decisions.
Has C15 been tested in people with bladder cancer?
No trial in people with bladder cancer appears in the studies described here. The BMC Medicine study’s human data were dietary cohort analyses, and its treatment experiments were done in cells and mice.
Is smoking a bigger bladder cancer risk than diet?
According to a 2024 review, tobacco smoking is the major risk factor for urothelial bladder cancer. A 2026 systematic review of 32 prospective cohorts found no strong or consistent link between individual dietary factors and bladder cancer incidence.
Does dairy raise or lower bladder cancer risk?
The evidence is mixed. A 2020 meta-analysis reported an inverse association with milk intake, while a 2024 review lists whole milk among factors linked to bladder cancer. Neither shows that dairy fat or C15 itself changes risk.
Does C15 prevent or treat cancer?
There is no evidence that it does in people. The findings so far are a dietary association in cohorts, effects in cell lines and one mouse tumour model. Anyone being treated for cancer should talk to their oncologist before taking any supplement.
What is the CCND3 finding?
In a 2025 screen of 94 cancer cell lines, lines that responded to C15 were more likely to carry a CCND3 mutation (4 of 18 against 1 of 61). The numbers are small and the finding has not been tested in animals or people [2].
References
- Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer. BMC Medicine, 2025
- Pentadecanoic Acid (C15:0) at Naturally Occurring Circulating Concentrations Has Selective Anticancer Activities Including Targeting B-Cell Lymphomas with CCND3 Oncogenic Alterations. Nutrients, 2025
- Miyajima K et al. Diet and risk of bladder cancer: a systematic review of epidemiological evidence. BJU international (2026). PMID 42634248
- Wu J et al. Dairy Product Consumption and Bladder Cancer Risk: A Meta-Analysis. Nutrition and cancer (2020). PMID 31295044
- Alouini S Risk Factors Associated with Urothelial Bladder Cancer. International journal of environmental research and public health (2024). PMID 39063530
- Pfeuffer M et al. Pentadecanoic and Heptadecanoic Acids: Multifaceted Odd-Chain Fatty Acids. Advances in nutrition (Bethesda, Md.) (2016). PMID 27422507
- Weitkunat K et al. Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate. The American journal of clinical nutrition (2017). PMID 28424190
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- To NB et al. Pentadecanoic Acid, an Odd-Chain Fatty Acid, Suppresses the Stemness of MCF-7/SC Human Breast Cancer Stem-Like Cells through JAK2/STAT3 Signaling. Nutrients (2020). PMID 32503225
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
